Wara Samar
4th April 2025
DoH Abu Dhabi, ADSCC Bring Advanced Gene Therapy for Sickle Cell Disease and Thalassemia to UAE
Abu Dhabi has taken a landmark step in healthcare with the introduction of CASGEVY, a revolutionary gene-editing therapy now available for the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Spearheaded by the Department of Health – Abu Dhabi (DoH) and the Abu Dhabi Stem Cells Center (ADSCC), this marks the first time such an advanced therapy is being offered in the UAE.
Developed using CRISPR/Cas9, the Nobel Prize-winning gene-editing technology, CASGEVY is designed to address the root causes of these inherited blood disorders. For patients and families who have lived with the burden of chronic pain, frequent hospital visits, and lifelong dependency on transfusions, this treatment offers the potential for long-term relief and a chance at a normal life. The first patient in the UAE is expected to begin therapy at Yas Clinic Hospital this April.
A One-Time Treatment with Long-Term Impact
Unlike traditional therapies, CASGEVY is a single-dose treatment that uses the patient’s own blood stem cells. These cells are extracted and modified in a lab to correct the genetic defect responsible for SCD and TDT. Once reintroduced into the body, the edited cells begin producing healthy red blood cells, offering lasting results. The treatment aims to reduce hospitalizations, lower dependency on blood transfusions, and improve overall quality of life.
CASGEVY will be covered by insurance, ensuring accessibility for patients who need it. This initiative is part of a broader effort to integrate cutting-edge therapies into the UAE’s healthcare system, making advanced medical solutions more widely available.
Advancing Abu Dhabi’s Position in Global Healthcare
The introduction of CASGEVY by DoH and ADSCC reinforces Abu Dhabi’s commitment to becoming a global leader in healthcare innovation. The emirate has established stringent safety regulations aligned with top international standards, ensuring that gene therapies are implemented responsibly and effectively. This milestone is the result of years of investment in medical research, strategic partnerships, and efforts to position Abu Dhabi as a biotechnology and life sciences hub.
With regulatory approval from the Emirates Drug Establishment (EDE) for patients aged 12 and above with severe SCD and TDT, CASGEVY marks a significant advancement in genetic medicine. More than just a new treatment, its arrival represents the UAE’s dedication to pioneering healthcare solutions that have the potential to change lives.
Join the Conversation at MedTech Malta 2025
From November 12 to 14, MedTech World will bring together global innovators, investors, and healthcare leaders in Valletta for MedTech Malta 2025. This is where ideas turn into action, connections lead to collaborations, and healthcare advancement takes center stage.
Whether you’re introducing new technology, exploring sponsorship opportunities, or engaging in discussions that drive progress, this is your chance to be part of something meaningful. Connect with key decision-makers, expand your network, and strengthen your presence in a rapidly evolving industry.
Spaces are limited—don’t miss out. Contact us at [email protected] to find out how you can get involved!
